The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype
Open accessAbstract
Melanoma is the most lethal skin cancer. Most deaths from melanoma result from metastases. Semaphorins have been shown to inhibit neuronal and endothelial cell migration, but the effects of semaphorins on tumor metastasis have not been documented. We found that semaphorin 3F (SEMA3F) was markedly downregulated in highly metastatic human cell lines in vitro and in vivo, which suggested that it may be a metastasis inhibitor. Metastatic human melanoma cells were transfected with SEMA3F and implanted into mice; the resultant tumors did not metastasize. Rather, the primary tumors resembled benign nevi characterized by large areas of apoptosis, diminished vascularity, inhibition of hyperplasia in overlying epidermal cells, and encapsulated tumor borders delineated by thick layers of fibroblasts and collagen matrix. This phenotype is in stark contrast to highly invasive, vascular mock-transfected tumors. In vitro, tumor cells expressing SEMA3F had a diminished capacity to adhere and migrate on fibronectin. Consistent with semaphorin-mediated chemorepulsion of neurons, tumor cells expressing SEMA3F were chemorepulsive for vascular and lymphatic endothelial cells expressing neuropilin-2 (NRP2), a novel mechanism for a tumor angiogenesis inhibitor. The repulsive activity was abrogated by NRP2 RNA interference. Together these results indicate that SEMA3F is a potent metastasis inhibitor that targets both tumor and stromal cells and raise the possibility of SEMA3F having therapeutic potential.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Soker, S., Takashima, S., Miao, H. Q., Neufeld, G., & Klagsbrun, M. (1998) · Cell · doi:10.1016/s0092-8674(00)81402-6 · Cited by 2,463
Self-citationNeuropilin Is a Semaphorin III Receptor
Kolodkin, A. L., Levengood, D. V., Rowe, E. G., Tai, Y.-T., Giger, R. J., & Ginty, D. D. (1997) · Cell · doi:10.1016/s0092-8674(00)80535-8 · Cited by 1,180
Neuropilin Is a Receptor for the Axonal Chemorepellent Semaphorin III
He, Z., & Tessier-Lavigne, M. (1997) · Cell · doi:10.1016/s0092-8674(00)80534-6 · Cited by 1,142
Fidler, I. J. (1990) · PubMed · Cited by 1,139
Plexin-Neuropilin-1 Complexes Form Functional Semaphorin-3A Receptors
Takahashi, T., Fournier, A., Nakamura, F., Wang, L.-H., Murakami, Y., Kalb, R. G., Fujisawa, H., & Strittmatter, S. M. (1999) · Cell · doi:10.1016/s0092-8674(00)80062-8 · Cited by 817
Lymphangiogenesis and cancer metastasis
Stacker, S. A., Achen, M. G., Jussila, L., Baldwin, M. E., & Alitalo, K. (2002) · Nature Reviews Cancer · doi:10.1038/nrc863 · Cited by 797
Chen, H., Chédotal, A., He, Z., Goodman, C. S., & Tessier-Lavigne, M. (1997) · Neuron · doi:10.1016/s0896-6273(00)80371-2 · Cited by 663
Kitsukawa, T., Shimizu, M., Sanbo, M., Hirata, T., Taniguchi, M., Bekku, Y., Yagi, T., & Fujisawa, H. (1997) · Neuron · doi:10.1016/s0896-6273(00)80392-x · Cited by 656
Abnormal lymphatic vessel development in neuropilin 2 mutant mice
Yuan, L., Moyon, D., Pardanaud, L., Bréant, C., Karkkainen, M. J., Alitalo, K., & Eichmann, A. (2002) · Development · doi:10.1242/dev.129.20.4797 · Cited by 632
Research works printed but not linked: 17
- 10.1006/geno.1999.5790 · doi:10.1006/geno.1999.5790
- Roche, 1996, Oncogene., 12, 1289
- Tse, 2002, Cancer Res., 62, 542
- Xiang, 2002, Cancer Res., 62, 2637
- Fidler, 1996, J. Investig. Dermatol. Symp. Proc., 1, 203
- 10.1006/geno.1996.0074 · doi:10.1006/geno.1996.0074
- 10.1136/jcp.54.3.196 · doi:10.1136/jcp.54.3.196
- Fidler, 1990, Cancer Res., 50, 6130
- Nasarre, 2003, Neoplasia., 5, 83, 10.1016/S1476-5586(03)80020-9 · doi:10.1016/s1476-5586(03)80020-9
- 10.1097/00008390-200308000-00007 · doi:10.1097/00008390-200308000-00007
- Srivastava, 1988, Am. J. Pathol., 133, 419
- Kim, 2000, Cancer Res., 60, 5410
- Kozlowski, 1984, J. Natl. Cancer Inst., 72, 913
- 10.1016/S0022-5347(01)66923-4 · doi:10.1016/s0022-5347(01)66923-4
- Pettaway, 1996, Clin. Cancer Res., 2, 1627
- Jussila, 1998, Cancer Res., 58, 1599
- Dong, 1999, Cancer Res., 59, 872
Cited by
Normalization of the Vasculature for Treatment of Cancer and Other Diseases
Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605
The senescence-associated secretory phenotype and its regulation
Lopes-Paciencia, S., Saint-Germain, E., Rowell, M.-C., Ruiz, A. F., Kalegari, P., & Ferbeyre, G. (2019) · Cytokine · doi:10.1016/j.cyto.2019.01.013 · Cited by 601
Semaphorins and their Signaling Mechanisms
Alto, L. T., & Terman, J. R. (2017) · Methods in Molecular Biology · doi:10.1007/978-1-4939-6448-2_1 · Cited by 429
The role of neuropilins in cancer
Ellis, L. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0538 · Cited by 263
Hypercholesterolemia Induces Angiogenesis and Accelerates Growth of Breast Tumors In Vivo
Pelton, K., Coticchia, C. M., Curatolo, A. S., Schaffner, C. P., Zurakowski, D., Solomon, K. R., & Moses, M. A. (2014) · The American Journal of Pathology · doi:10.1016/j.ajpath.2014.03.006 · Cited by 109
Metadata
- Authors
- Bielenberg, D. R., Hida, Y., Shimizu, A., Kaipainen, A., Kreuter, M., Kim, C. C., & Klagsbrun, M.
- Venue
- Journal of Clinical Investigation
- Published
- 2004-11-01
- Volume
- 114
- Issue
- 9
- Pages
- 1260-1271
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2096643761
- Cited by
- 286
- References
- 55
- FWCI
- 6.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype. https://app.cochat.ai/papers/10.1172/jci200421378
- The paper
- Bielenberg, D. R., Hida, Y., Shimizu, A., Kaipainen, A., Kreuter, M., Kim, C. C., & Klagsbrun, M. (2004). Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype. Journal of Clinical Investigation. https://doi.org/10.1172/jci200421378
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
